A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors (NCT02099058)

🧪 Interventions in This Study

• Osimertinib (DRUG)
• Nivolumab (DRUG)
• Telisotuzumab vedotin (DRUG)
• Telisotuzumab vedotin (DRUG)
• Erlotinib (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (36 Sites)

Showing the first 25 of 36 sites.

• Scottsdale Healthcare /ID# 123761 — Scottsdale, Arizona
• City of Hope /ID# 153759 — Duarte, California
• University of California, Los Angeles /ID# 148295 — Los Angeles, California
• UC Irvine /ID# 165107 — Orange, California
• University of California, Davis Comprehensive Cancer Center /ID# 129805 — Sacramento, California
• Univ of Colorado Cancer Center /ID# 123759 — Aurora, Colorado
• The University of Chicago Medical Center /ID# 136995 — Chicago, Illinois
• Ingalls Memorial Hosp /ID# 165876 — Harvey, Illinois
• Massachusetts General Hospital /ID# 129804 — Boston, Massachusetts
• Dana-Farber Cancer Institute /ID# 168782 — Boston, Massachusetts
• Duplicate_Henry Ford Health System /ID# 149857 — Detroit, Michigan
• Herbert Herman Cancer Center /ID# 149858 — Lansing, Michigan
• Washington University-School of Medicine /ID# 143798 — St Louis, Missouri
• Summit Medical Group-Florham Park /ID# 217651 — Florham Park, New Jersey
• Northwell Health - Monter Cancer Center /ID# 218170 — Lake Success, New York
• Montefiore Medical Park at Eastchester /ID# 218445 — The Bronx, New York
• Duke Cancer Center /ID# 123763 — Durham, North Carolina
• Tennessee Oncology, PLLC /ID# 129802 — Nashville, Tennessee
• Mary Crowley Cancer Research /ID# 123760 — Dallas, Texas
• University of Texas MD Anderson Cancer Center /ID# 154648 — Houston, Texas
• Virginia Cancer Specialists - Fairfax /ID# 165708 — Fairfax, Virginia
• Universitair Ziekenhuis Antwerpen /ID# 170118 — Edegem, Antwerpen
• Duplicate_Tampere University Hospital /ID# 165065 — Tampere, Pirkanmaa
• AP-HM - Hopital de la Timone /ID# 151570 — Marseille, Bouches-du-Rhone
• Institut Gustave Roussy /ID# 132747 — Villejuif, Val-de-Marne

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced Solid Tumors Cancer

• Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors — Boston, Massachusetts
• Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors — Springdale, Arkansas
• A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors — Los Angeles, California
• A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors. — Los Angeles, California
• ORB-021 In Patients With Advanced Solid Tumors — Scottsdale, Arizona

Explore by condition: All Advanced Solid Tumors Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.